1. Home
  2. CRBP vs SRL Comparison

CRBP vs SRL Comparison

Compare CRBP & SRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBP
  • SRL
  • Stock Information
  • Founded
  • CRBP 2009
  • SRL 2017
  • Country
  • CRBP United States
  • SRL China
  • Employees
  • CRBP N/A
  • SRL N/A
  • Industry
  • CRBP Biotechnology: Pharmaceutical Preparations
  • SRL Professional Services
  • Sector
  • CRBP Health Care
  • SRL Consumer Discretionary
  • Exchange
  • CRBP Nasdaq
  • SRL Nasdaq
  • Market Cap
  • CRBP 110.3M
  • SRL 89.5M
  • IPO Year
  • CRBP N/A
  • SRL N/A
  • Fundamental
  • Price
  • CRBP $8.90
  • SRL $5.76
  • Analyst Decision
  • CRBP Strong Buy
  • SRL
  • Analyst Count
  • CRBP 10
  • SRL 0
  • Target Price
  • CRBP $53.56
  • SRL N/A
  • AVG Volume (30 Days)
  • CRBP 124.3K
  • SRL 4.4K
  • Earning Date
  • CRBP 08-05-2025
  • SRL 08-12-2025
  • Dividend Yield
  • CRBP N/A
  • SRL 18.09%
  • EPS Growth
  • CRBP N/A
  • SRL N/A
  • EPS
  • CRBP N/A
  • SRL N/A
  • Revenue
  • CRBP N/A
  • SRL $24,535,042.00
  • Revenue This Year
  • CRBP N/A
  • SRL N/A
  • Revenue Next Year
  • CRBP $270.04
  • SRL N/A
  • P/E Ratio
  • CRBP N/A
  • SRL N/A
  • Revenue Growth
  • CRBP N/A
  • SRL N/A
  • 52 Week Low
  • CRBP $4.64
  • SRL $5.52
  • 52 Week High
  • CRBP $61.89
  • SRL $9.99
  • Technical
  • Relative Strength Index (RSI)
  • CRBP 53.56
  • SRL 38.77
  • Support Level
  • CRBP $9.10
  • SRL $5.51
  • Resistance Level
  • CRBP $9.80
  • SRL $6.21
  • Average True Range (ATR)
  • CRBP 0.62
  • SRL 0.25
  • MACD
  • CRBP 0.01
  • SRL -0.02
  • Stochastic Oscillator
  • CRBP 31.45
  • SRL 30.12

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About SRL Scully Royalty Ltd.

Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.

Share on Social Networks: